Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases. Gilead Sciences Inc has a market cap of $93.8 billion; its shares were traded at around $71.81 with a P/E ratio of 8.15 and P/S ratio of 3.43. The dividend yield of Gilead Sciences Inc stocks is 2.84%. Gilead Sciences Inc had annual average EBITDA growth of 53.00% over the past five years.
CEO Recent Trades:
- President and CEO John F Milligan sold 220,000 shares of GILD stock on 11/13/2017 at the average price of $72.88. The price of the stock has decreased by 1.47% since.
Directors and Officers Recent Trades:
- EVP Comm&Acs ALA, Corp&Med Aff Gregg H Alton sold 15,000 shares of GILD stock on 11/01/2017 at the average price of $74.82. The price of the stock has decreased by 4.02% since.
- Executive Chairman John C Martin sold 73,333 shares of GILD stock on 11/01/2017 at the average price of $75.13. The price of the stock has decreased by 4.42% since.
.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .